Skip to content

ESC 2021: acute and chronic heart failure

International ESC Current

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

McDonagh TA, et al. Eur Heart J. 2021;42:3599–3726
DOI 10.1093/eurheartj/ehab368 · Summary checked against the source: 2026-11

Read or download the original

Read with the 2023 focused update

The ESC 2023 focused update upgraded SGLT2 inhibitors in HFmrEF and HFpEF to Class I, upgraded IV iron, and added a post-discharge up-titration recommendation. Where this page and the update differ, follow the update.

At a glance

  1. Diagnosis: NT-proBNP ≥125 or BNP ≥35, then echocardiography, then classify by LVEF. [p. 3615]
  2. HFrEF: four Class I drugs for everyone: ACE-I (or ARNI as a replacement), beta-blocker, MRA, and dapagliflozin or empagliflozin. Add loop diuretics for congestion. [p. 3620]
  3. ICD: Class I if ischaemic, IIa if non-ischaemic. LVEF ≤35% after ≥3 months of optimal therapy. [p. 3625]
  4. CRT: Class I for LBBB with QRS ≥150 ms. IIa for LBBB 130–149 ms or non-LBBB ≥150 ms. Not for QRS <130. [p. 3627]
  5. HFmrEF: everything except diuretics was IIb in 2021 (SGLT2i is now Class I under the 2023 update). [p. 3629]
  6. Acute HF: check for cardiogenic shock or respiratory failure first, then a CHAMPIT cause. Use IV loop diuretics and judge the response by urine sodium and urine output. [p. 3653–3654]

Definitions

Adapted from ESC 2021 Table 3 [p. 3613]

HFrEF HFmrEF HFpEF
1 Symptoms ± signs Symptoms ± signs Symptoms ± signs
2 LVEF ≤40% LVEF 41–49% LVEF ≥50%
3 – – Objective evidence of structural or functional abnormality consistent with LV diastolic dysfunction or raised filling pressure, including raised natriuretic peptides

For HFmrEF, other evidence of structural heart disease (larger left atrium, LV hypertrophy, abnormal LV filling) makes the diagnosis more likely.

Diagnosis

flowchart TD
    A["Suspected HF<br/>risk factors · symptoms and/or signs · abnormal ECG"] --> B{"NT-proBNP ≥125 pg/mL<br/>or BNP ≥35 pg/mL?"}
    B -- No --> U["HF unlikely<br/>consider other diagnoses"]
    B -- "Yes (or HF strongly suspected,<br/>or NP not available)" --> E["Echocardiography"]
    E --> F{"Abnormal findings?"}
    F -- No --> U
    F -- Yes --> C["HF confirmed<br/>define phenotype by LVEF"]
    C --> R["≤40%<br/>HFrEF"]
    C --> M["41–49%<br/>HFmrEF"]
    C --> P["≥50%<br/>HFpEF"]
    R --> T["Find the cause and start treatment"]
    M --> T
    P --> T
Adapted from ESC 2021 Figure 1 [p. 3615]

HFrEF

flowchart TD
    A["Class I for all with HFrEF:<br/>ACE-I (or ARNI as replacement) · beta-blocker · MRA<br/>dapagliflozin / empagliflozin · loop diuretic for fluid retention"] --> B{"Device criteria"}
    B -- "LVEF ≤35%, QRS <130 ms,<br/>where appropriate" --> I["ICD<br/>ischaemic: Class I<br/>non-ischaemic: Class IIa"]
    B -- "LVEF >35%, or device<br/>not indicated or appropriate" --> S
    B -- "Sinus rhythm, LVEF ≤35%,<br/>QRS ≥130 ms" --> C["CRT-D / CRT-P<br/>QRS 130–149 ms: IIa<br/>QRS ≥150 ms: I"]
    I --> S["If symptoms persist,<br/>consider Class II therapies"]
    C --> S
Adapted from ESC 2021 Figure 2 [p. 3620]

Class I: drugs for all patients with HFrEF (NYHA II–IV) [p. 3620]

  • ACE-I [I, A]
  • Beta-blocker [I, A]
  • MRA [I, A]
  • Dapagliflozin or empagliflozin [I, A]
  • Sacubitril/valsartan as a replacement for an ACE-I [I, B]

Class I: in selected patients [p. 3622]

  • Loop diuretics for signs or symptoms of congestion. [I, C]
  • ARB (candesartan, losartan or valsartan) if the patient can't tolerate an ACE-I or ARNI. They should still get a beta-blocker and an MRA. [I, B]

Class IIa [p. 3622]

  • Ivabradine: LVEF ≤35%, sinus rhythm, resting HR ≥70 despite the maximum tolerated beta-blocker plus ACE-I/ARNI and MRA [IIa, B]. Also when a beta-blocker can't be used [IIa, C].
  • Hydralazine + isosorbide dinitrate: self-identified Black patients with LVEF ≤35% (or <45% with a dilated LV), NYHA III–IV, despite ACE-I/ARNI, beta-blocker and MRA. [IIa, B]

Class IIb [p. 3622–3623]

  • Vericiguat: NYHA II–IV with worsening HF despite standard therapy. [IIb, B]
  • Hydralazine + isosorbide dinitrate if an ACE-I, ARB and ARNI can't be used. [IIb, B]
  • Digoxin in sinus rhythm despite standard therapy, to reduce admissions. [IIb, B]
  • Sacubitril/valsartan started without a previous ACE-I (de novo). [IIb, B · text p. 3622]

Starting ARNI

The patient needs adequate BP and eGFR ≥30. Leave a 36-hour washout after the last ACE-I dose. [p. 3622]

Devices

ICD: Class I [p. 3625]

  • Secondary prevention: after recovering from a ventricular arrhythmia that caused haemodynamic instability, with expected survival >1 year in good functional status. Exclusions: a reversible cause, or the arrhythmia occurred <48 h after an MI. [I, A]
  • Primary prevention, ischaemic: NYHA II–III, LVEF ≤35% despite ≥3 months of optimal therapy, and not within 40 days of an MI. [I, A]

ICD: Class IIa

  • Primary prevention, non-ischaemic: NYHA II–III, LVEF ≤35% despite ≥3 months of optimal therapy. [IIa, A]

CRT: Class I [p. 3627]

  • Symptomatic, sinus rhythm, QRS ≥150 ms, LBBB, LVEF ≤35% despite optimal therapy. [I, A]
  • CRT rather than RV pacing for HFrEF with an indication for ventricular pacing (high-degree AV block), whatever the NYHA class or QRS width. This includes AF. [I, A]

CRT: Class IIa

  • QRS ≥150 ms, non-LBBB. [IIa, B]
  • QRS 130–149 ms, LBBB. [IIa, B]
  • Upgrade a pacemaker or ICD to CRT if HF worsens despite therapy and the patient has a high proportion of RV pacing. [IIa, B]

CRT: Class IIb

  • QRS 130–149 ms, non-LBBB. [IIb, B]

Class III

  • ICD within 40 days of an MI. [III, A]
  • ICD in NYHA IV with refractory symptoms, unless a candidate for CRT, VAD or transplant. [III, C]
  • CRT with QRS <130 ms and no pacing indication. [III, A]

HFmrEF and HFpEF (2021)

Adapted from ESC 2021 p. 3629 [p. 3629]

Drug Class
Diuretics for congestion I, C
ACE-I IIb, C
ARB IIb, C
Beta-blocker IIb, C
MRA IIb, C
Sacubitril/valsartan IIb, C

Updated in 2023: SGLT2i is now Class I, A.

  • Screen for and treat the cause, plus cardiovascular and non-cardiovascular comorbidities (Class I).
  • Diuretics for congestion (Class I).
  • Updated in 2023: SGLT2i is now Class I, A. See the 2023 update.

Acute heart failure

flowchart TD
    A["Suspected acute HF<br/>(urgent phase after first contact)"] --> B{"Cardiogenic shock and/or<br/>respiratory failure?"}
    B -- Yes --> S["Pharmacological support<br/>ventilatory support<br/>mechanical circulatory support"]
    B -- No --> C["Immediate phase (first 60–120 min):<br/>identify the acute cause — CHAMPIT"]
    C --> D{"C acute coronary syndrome<br/>H hypertensive emergency<br/>A arrhythmia<br/>M mechanical cause<br/>P pulmonary embolism<br/>I infection<br/>T tamponade"}
    D -- Yes --> T["Start specific treatment straight away"]
    D -- No --> F["Further treatment by clinical presentation"]
Adapted from ESC 2021 Figure 12 [p. 3653]

Four clinical presentations

Adapted from ESC 2021 Table 21 [p. 3647]

Acute decompensated HF Acute pulmonary oedema Isolated RV failure Cardiogenic shock
Mechanism LV dysfunction, sodium and water retention Raised afterload and/or LV diastolic dysfunction, valve disease RV dysfunction and/or pre-capillary pulmonary hypertension Severe cardiac dysfunction
Onset Gradual (days) Rapid (hours) Gradual or rapid Gradual or rapid
Blood pressure Normal to low Normal to high Low Low
Profile Wet–warm or wet–cold Wet–warm Wet–cold Wet–cold
Main treatment Diuretics; inotropes or vasopressors if hypoperfused; short-term MCS or RRT if needed Diuretics, vasodilators Diuretics for congestion; inotropes or vasopressors if hypoperfused Inotropes or vasopressors, short-term MCS, RRT

Diuretics in acute HF

flowchart TD
    A{"Already on an oral loop diuretic?"} -- No --> B["IV furosemide 20–40 mg"]
    A -- Yes --> C["IV dose = 1–2 × the daily oral dose"]
    B --> D{"Spot urine sodium ≥50–70 mEq/L at 2 h<br/>or urine output ≥100–150 mL/h at 6 h?"}
    C --> D
    D -- Yes --> E["Repeat the same dose IV every 12 h"]
    D -- No --> F["Double the IV dose<br/>up to the maximum IV dose"]
    E --> G{"Urine sodium ≥50–70 mEq/L<br/>or urine output ≥100–150 mL/h?"}
    F --> G
    G -- Yes --> H["Continue until fully decongested"]
    G -- No --> I["Combination diuretics<br/>(add thiazide, metolazone or acetazolamide)"]
    H -.- K["Check creatinine and electrolytes at least every 24 h"]
    I -.- K
Adapted from ESC 2021 Figure 13 [p. 3654]. The maximum daily IV loop dose is usually 400–600 mg of furosemide (up to 1000 mg in severe kidney impairment).

Class I: initial treatment of acute HF [p. 3655–3656]

  • Oxygen if SpO₂ <90% or PaO₂ <60 mmHg. [I, C]
  • Intubation for progressive respiratory failure despite oxygen or non-invasive ventilation. [I, C]
  • IV loop diuretics for every patient admitted with signs or symptoms of fluid overload. [I, C]
  • Thromboembolism prophylaxis (for example LMWH) if not already anticoagulated. [I, A]

Class IIa

  • Non-invasive positive pressure ventilation for respiratory distress (RR >25, SpO₂ <90%), started as early as possible. [IIa, B]
  • Loop + thiazide-type diuretic for resistant oedema. [IIa, B]

Class IIb

  • IV vasodilators as first treatment if SBP >110 mmHg. [IIb, B]
  • Inotropes if SBP <90 mmHg with hypoperfusion not responding to standard treatment. [IIb, C]
  • Vasopressor, preferably noradrenaline, in cardiogenic shock. [IIb, B]

Class III

  • Routine inotropes (unless symptomatic hypotension with hypoperfusion). [III, C]
  • Routine opiates (unless severe or intractable pain or anxiety). [III, C]

Iron deficiency (2021 version)

Class I [p. 3669]

  • Screen all patients with HF for anaemia and iron deficiency: FBC, ferritin and TSAT. [I, C]

Class IIa (upgraded in 2023)

  • IV ferric carboxymaltose for symptomatic LVEF <45% with iron deficiency, for symptoms, exercise capacity and quality of life. [IIa, A]
  • The same after a recent HF admission with LVEF <50%, to reduce rehospitalisation. [IIa, B]

Iron deficiency = serum ferritin <100 ng/mL, or ferritin 100–299 ng/mL with TSAT <20%. Erythropoiesis-stimulating agents aren't indicated for anaemia in HF.

Clinical pearls

  • ESC uses CHAMPIT for the acute causes of HF.
  • In the non-acute setting, NT-proBNP <125 makes HF unlikely.
  • ESC 2021 dropped "mid-range" and renamed HFmrEF "mildly reduced".
  • Diuretic response after IV furosemide: urine sodium >50–70 mEq/L at 2 h, or urine output >100–150 mL/h over the first 6 h.
  • Small, transient rises in creatinine during decongestion aren't linked to worse outcomes once the patient is free of congestion. When starting a RAAS inhibitor, ARNI or SGLT2i, a creatinine rise of <50% (up to 266 µmol/L) or an eGFR fall of <10% is acceptable. [p. 3669]

Classes and levels of evidence

How ESC 2021 grades its recommendations. Adapted from ESC 2021 Tables 1 and 2 [p. 3608]. Hover over any class or level cited on this page to see what it means.

Class Meaning Wording used
Class I Evidence and/or general agreement that a treatment or procedure is beneficial, useful and effective is recommended or is indicated
Class IIa Weight of evidence or opinion is in favour of usefulness or efficacy should be considered
Class IIb Usefulness or efficacy is less well established by evidence or opinion may be considered
Class III Evidence or general agreement that the treatment or procedure isn't useful or effective, and in some cases may be harmful is not recommended
Level Meaning
Level A Data from multiple randomised clinical trials or meta-analyses
Level B Data from a single randomised clinical trial or large non-randomised studies
Level C Consensus of expert opinion and/or small studies, retrospective studies, registries

Class II covers conflicting evidence or a divergence of opinion about usefulness or efficacy. It's split into IIa and IIb.